As the price of specialty drugs continue to rise, employers are desperately seeking to rein in their health care costs. 

According to a recent survey of 487 large employers by Towers Watson and the National Business Group on Health, 80 percent of firms said that design changes to health and pharmacy plans represents the most significant strategic priority over the next three years. 

More than half of employers (53 percent), said they have imposed new restrictions on specialty drugs, such as requiring prior authorization for prescriptions or limiting use based on clinical evidence. By 2018, a full 85 percent of employers plan to have such restrictions in place. 

Complete your profile to continue reading and get FREE access to BenefitsPRO, part of your ALM digital membership.

  • Critical BenefitsPRO information including cutting edge post-reform success strategies, access to educational webcasts and videos, resources from industry leaders, and informative Newsletters.
  • Exclusive discounts on ALM, BenefitsPRO magazine and events
  • Access to other award-winning ALM websites including and

© 2024 ALM Global, LLC, All Rights Reserved. Request academic re-use from All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.